Payment overview · 2025
General Payments
$1,136.54
48 reported records · 17 companies
Healthcare provider profile · identity verified
Akisha Wilson, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BRENTWOOD, NY · NPI 1861860611
Verified facts
What the public records show
CMS Open Payments records show Akisha Wilson, NP received $1,136.54 in general payments during 2025 across 48 reported records.
ABBVIE INC. accounted for 16.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $183.44 | 16.1% | 7 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $165.24 | 14.5% | 7 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $141.61 | 12.5% | 7 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $114.33 | 10.1% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $99.24 | 8.7% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $72.58 | 6.4% | 3 | 2025 |
| Neos Therapeutics, LP | Unresolved — no canonical attribution shown | $64.34 | 5.7% | 2 | 2025 |
| Luye Pharma (USA) Ltd. | Unresolved — no canonical attribution shown | $51.13 | 4.5% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $49.08 | 4.3% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $43.93 | 3.9% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.99 | 2.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.97 | 2.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.91 | 2.1% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $22.54 | 2.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $21.87 | 1.9% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $16.65 | 1.5% | 1 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.69 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,136.54 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $183.44 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $165.24 | 7 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $141.61 | 7 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $110.21 | 5 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $99.24 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $72.58 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $67.80 | 4 | 2025 |
Source payment records
|
|||||
| EXXUA Normalized: exxua |
Drug | Neos Therapeutics, LP | $64.34 | 2 | 2025 |
Source payment records
|
|||||
| ERZOFRI EXTENDED-RELEASE Normalized: erzofri extended release |
Drug | Luye Pharma (USA) Ltd. | $51.13 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $49.08 | 2 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $46.53 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $43.93 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $43.50 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $26.99 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $23.97 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $22.54 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $15.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 35 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | 24 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
35 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 558 | 263 |
| Amlodipine Besylate | Amlodipine Besylate | 394 | 181 |
| Levothyroxine Sodium | Levothyroxine Sodium | 339 | 141 |
| Losartan Potassium | Losartan Potassium | 273 | 128 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 261 | 120 |
| Metoprolol Succinate | Metoprolol Succinate | 231 | 104 |
| Omeprazole | Omeprazole | 194 | 91 |
| Simvastatin | Simvastatin | 160 | 67 |
| Lisinopril | Lisinopril | 159 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 75 |
| Metformin Hcl | Metformin Hcl | 139 | 66 |
| Metformin Hcl Er | Metformin Hcl | 113 | 58 |
| Alprazolam | Alprazolam | 111 | 66 |
| Meloxicam | Meloxicam | 107 | 37 |
| Famotidine | Famotidine | 100 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 90 | 40 |
| Sertraline Hcl | Sertraline Hcl | 84 | 41 |
| Gabapentin | Gabapentin | 82 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 35 |
| Eliquis | Apixaban | 74 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 36 |
| Ezetimibe | Ezetimibe | 69 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 28 |
| Allopurinol | Allopurinol | 62 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 23 |
| Furosemide | Furosemide | 57 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 29 |
| Atenolol | Atenolol | 55 | 26 |
| Valsartan | Valsartan | 55 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 23 |
| Montelukast Sodium | Montelukast Sodium | 54 | 25 |
| Synthroid | Levothyroxine Sodium | 52 | 24 |
| Azithromycin | Azithromycin | 47 | 45 |
| Jardiance | Empagliflozin | 47 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 46 | 18 |
| Ramipril | Ramipril | 45 | 17 |
| Bupropion Xl | Bupropion Hcl | 44 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 24 |
| Methylprednisolone | Methylprednisolone | 38 | 38 |
| Trazodone Hcl | Trazodone Hcl | 37 | 14 |
| Clonazepam | Clonazepam | 36 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | 16 |
| Januvia | Sitagliptin Phosphate | 35 | 12 |
| Ozempic | Semaglutide | 35 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | 14 |
| Xarelto | Rivaroxaban | 35 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | 17 |
| Carvedilol | Carvedilol | 32 | 18 |
| Glimepiride | Glimepiride | 32 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 28 | 12 |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 27 |
| Diazepam | Diazepam | 27 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 17 |
| Spironolactone | Spironolactone | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | 13 |
| Potassium Chloride | Potassium Chloride | 23 | 11 |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 18 |
| Irbesartan | Irbesartan | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,136.54 · 48 records | ABBVIE INC. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, APLENZIN, ARISTADA, AUSTEDO XR, Auvelity, Azstarys, CAPLYTA, Dexcom G6 Transmitter, ERZOFRI EXTENDED-RELEASE, EXXUA, FANAPT, LYBALVI, Ozempic, REXULTI, SPRAVATO, TRINTELLIX, UNITHROID, UZEDY, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error